Obiettivo
Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinically test them. Our hypothesis is that a focus on cross-species endophenotypes, finding biologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g. cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of sMRI and fMRI-based endophenotypes in genetically-selected healthy volunteers, infants at risk for ASD, and children and adults (including twins) with and without ASD, as early and surrogate markers for efficacy; and to combine this with PET approaches to provide guidance regarding optimal clinical trial design; and c) identify biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms) and will actively collaborate with patient groups and other international efforts (e.g. the Autism Genetic Resource Exchange (AGRE)).
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesneurobiologycognitive neuroscience
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Invito a presentare proposte
IMI-JU-03-2010
Vedi altri progetti per questo bando
Meccanismo di finanziamento
JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)Coordinatore
4070 Basel
Svizzera
Mostra sulla mappa
Partecipanti (26)
WC2R 2LS London
Mostra sulla mappa
68159 Mannheim
Mostra sulla mappa
6525 XZ Nijmegen
Mostra sulla mappa
CB2 1TN Cambridge
Mostra sulla mappa
Partecipazione conclusa
101 Reykjavik
Mostra sulla mappa
3584 CX Utrecht
Mostra sulla mappa
4051 Basel
Mostra sulla mappa
75724 Paris
Mostra sulla mappa
Partecipazione conclusa
80333 Muenchen
Mostra sulla mappa
80539 Munchen
Mostra sulla mappa
69117 Heidelberg
Mostra sulla mappa
Partecipazione conclusa
2750 Ballerup
Mostra sulla mappa
17177 Stockholm
Mostra sulla mappa
RG21 4FA Basingstoke
Mostra sulla mappa
2340 Beerse
Mostra sulla mappa
91190 GIF-SUR-YVETTE
Mostra sulla mappa
1752 Villars-sur-Glâne
Mostra sulla mappa
WC1E 7HX London
Mostra sulla mappa
00128 Roma
Mostra sulla mappa
08540 Princeton Nj
Mostra sulla mappa
CT13 9NJ Sandwich
Mostra sulla mappa
75015 PARIS 15
Mostra sulla mappa
89081 Ulm
Mostra sulla mappa
6709 PA Wageningen
Mostra sulla mappa
101 Reykjavik
Mostra sulla mappa
75008 Paris
Mostra sulla mappa